The Oxidized Phospholipid PGPC Impairs Angiogenesis by Inhibiting Endothelial Autophagosomal-Lysosomal Fusion Through NPC1-Induced Syntaxin 17 Acetylation and Ubiquitination.

PGPC impairs angiogenesis by promoting degradation of STX17, inhibiting autophagosomal-lysosomal fusion in endothelial cells, with significant effects observed in ischemic heart models.

• Why it matters: Understanding how oxidized phospholipids like PGPC influence autophagy and angiogenesis is crucial for developing therapies for ischemic heart disease and coronary artery disease, where impaired blood vessel formation worsens outcomes.
• What they did: The study quantified plasma PGPC levels in CAD patients and evaluated its effects on endothelial cell functions and in vivo models, analyzing autophagic flux, protein modifications, and interactions involving NPC1, STX17, and VAMP8.
• The result: PGPC increased NPC1 expression, leading to enhanced degradation of STX17 and inhibition of autophagic flux, which suppressed angiogenesis; interventions restoring autophagy reversed these effects, suggesting new therapeutic targets.